Posted in | News | Medical Sensor

OrthoSensor Achieves CE Mark for VERASENSE Knee System, Plans European Launch

OrthoSensor announced today plans to launch its VERASENSE Knee System in European markets after recently receiving CE Mark approval. VERASENSE is the first integrated intelligent orthopaedic device to provide surgeons with real-time quantitative data on knee implant positioning, limb alignment and soft tissue balance during total knee replacement surgery.

"We're pleased to have successfully achieved CE Mark for our VERASENSE technology. This enables us to provide OrthoSensor's innovative technology to orthopaedic surgeons and patients in markets outside the US and creates significant growth opportunities for our business," said Jay Pierce, President and CEO of OrthoSensor, Inc. "It's a vital step toward expanding our business internationally."

VERASENSE was cleared for use in total knee replacement procedures by the U.S. Food and Drug Administration (FDA) in 2009 and received FDA clearance for limb alignment earlier this year. First clinical use was September 2011.

The VERASENSE Knee System is an intelligent single-use instrument system that replaces the standard plastic tibial trial spacer used during knee replacement surgery. VERASENSE proprietary software and advanced sensor and real-time data communications technologies empower surgeons to make evidence-based decisions regarding component placement, limb alignment and soft tissue balance to achieve balance and stability through a full range of motion with the goal of optimizing clinical outcomes and enhancing patient satisfaction.

VERASENSE integrates seamlessly into the surgical workflow and is compatible for use with multiple leading knee implant systems.

About OrthoSensor
OrthoSensor, Inc. develops and commercializes intelligent orthopaedic devices and data services that provide quantitative feedback to surgeons and hospitals during surgery and post-operatively. The company's intelligent orthopaedic devices utilize proprietary software, as well as advanced sensor and communications technologies, to enable evidence-based surgical decisions with the goal of improving patient outcomes and reducing the cost of treating musculoskeletal disease.

OrthoSensor and VERASENSE are trademarks of OrthoSensor, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Stryker Corporation. (2019, February 24). OrthoSensor Achieves CE Mark for VERASENSE Knee System, Plans European Launch. AZoSensors. Retrieved on November 21, 2024 from https://www.azosensors.com/news.aspx?newsID=6695.

  • MLA

    Stryker Corporation. "OrthoSensor Achieves CE Mark for VERASENSE Knee System, Plans European Launch". AZoSensors. 21 November 2024. <https://www.azosensors.com/news.aspx?newsID=6695>.

  • Chicago

    Stryker Corporation. "OrthoSensor Achieves CE Mark for VERASENSE Knee System, Plans European Launch". AZoSensors. https://www.azosensors.com/news.aspx?newsID=6695. (accessed November 21, 2024).

  • Harvard

    Stryker Corporation. 2019. OrthoSensor Achieves CE Mark for VERASENSE Knee System, Plans European Launch. AZoSensors, viewed 21 November 2024, https://www.azosensors.com/news.aspx?newsID=6695.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.